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Abstract Dapsone (4,40-diaminodiphenylsulfone) is an
aniline derivative belonging to the group of synthetic
sulfones. In 1937 against the background of sulfonamide
era the microbial activity of dapsone has been discovered.
Shortly thereafter, the use of dapsone to treat non-patho-
gen-caused diseases revealed alternate antiinflammatory
mechanisms that initially were elucidated by inflammatory
animal models. Thus, dapsone clearly has dual functions of
both: antimicrobial/antiprotozoal effects and anti-inflam-
matory features similarly to non-steroidal anti-inflamma-
tory drugs. The latter capabilities primarily were used in
treating chronic inflammatory disorders. Dapsone has been
investigated predominantly by in vitro methods aiming to
get more insights into the effect of dapsone to inflamma-
tory effector cells, cytokines, and/or mediators, such as
cellular toxic oxygen metabolism, myoloperoxidase-/halo-
genid system, adhesion molecules, chemotaxis, membrane-
associated phospholipids, prostaglandins, leukotrienes,
interleukin-8, tumor necrosis factor a, lymphocyte func-
tions, and tumor growth. Moreover, attention has been paid
to mechanisms by which dapsone mediates effects in more
complex settings like impact of lifespan, stroke, glioblas-
toma, or as anticonvulsive agent. Additionally, there are
some dermatological investigations in human being using
dapsone and its metabolites (e.g., leukotriene B4-induced
chemotaxis, ultraviolet-induced erythema). It could be
established that dapsone metabolites by their own have
anti-inflammatory properties. Pharmacology and mecha-
nisms of action are determining factors for clinical use of
dapsone chiefly in neutrophilic and/or eosinophilic der-
matoses and in chronic disorders outside the field of der-
matology. The steroid-sparing effect of dapsone is useful
for numerous clinical entities. Future avenues of investi-
gations will provide more information on this fascinating
and essential agent.
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TNFa Tumor necrosis factor a
UDP Uridine diphosphate
UVA/UVB Ultraviolet A/B
VEGF/VEGFR Vascular endothelial growth factor/
VEGF receptor
Introduction
Dapsone was first synthesized in 1908 [63]. At that time,
dapsone was not envisioned as a therapeutic agent, but was
the result of pure chemical science ambition. Sulfone
research in medicine started in 1937, when two groups in
England and France were the first to investigate dapsone as
an antimicrobial agent in the framework of sulfonamide
research [22, 43, 59]. In this context, it is remarkable that
certain congeners, but not the so-called parent sulfone
dapsone, were the first sulfones used to treat gonorrhea [18,
123]. Later, introduction into the therapy of non-infectious
diseases was not the result of systematic research, but
virtually driven by fortune [170, 173].
Concerning the mechanisms of action, dapsone is
characterized by dual function. It combines both anti-
microbial/antiprotozoal properties and anti-inflammatory
effects resembling those of non-steroidal anti-inflammatory
drugs. In past decades, especially the hematological
adverse effects of dapsone have induced intense efforts to
develop substituted sulfones with improved risk–benefit-
ratio. A parallel goal of research was the synthesis of
parenteral application modalities. Interestingly, however,
still today the oral application of dapsone constitutes the
only sulfone used in systemic therapy.
The changeful history of dapsone has been covered in
detail in the literature [47, 165, 170]. Therefore, this issue
has been omitted from this survey. Rather, this paper will
focus on the mechanisms of action of dapsone and consider
important indications in dermatology and beyond as well as
therapeutic consequences. In order to understand the
mechanisms of action of sulfone and its adverse effects,
knowledge of its pharmacology and metabolism in human
beings and in inflammatory cells is mandatory.
Chemistry and pharmacology
Chemically, dapsone is an aniline derivative. As a sulfone,
it shows the structure of a sulphur atom linking to two
carbon atoms (Fig. 1). Solubility of dapsone varies over a
wide range depending on the solvent used (e.g. water,
0.2 mg/mL vs. methanol, 52 mg/mL). Following oral
administration, dapsone is almost completely absorbed
from the gut with bioavailability exceeding 86 %. Peak
serum concentrations are attained within 2–8 h. After
ingestion of a single 50–300 mg dose of dapsone, maxi-
mum serum concentrations range from 0.63 to 4.82 mg/L
[2, 165, 181]. Under steady-state conditions, 100 mg/day
(the dose most frequently used) results in serum concen-
trations of 3.26 mg/L (maximum) and 1.95 mg/L (after
24 h) [2, 41, 181]. These dapsone serum concentrations
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attained in vivo must be kept in mind when interpreting the
results of in vitro investigations (see below). After
absorption, dapsone undergoes enterohepatic circulation. It
is metabolized by the liver but also by activated poly-
morphonuclear leukocytes (PMN) and mononuclear cells
[152, 156]. In the liver, dapsone is metabolized primarily
through acetylation by N-acetyltransferase to monoacteyl-
dapsone (MADDS), and through hydroxylation by cyto-
chrome P-450 enzymes, resulting in the generation of
dapsone hydroxylamine (DDS-NOH) (Fig. 2). In fact,
administration of dapsone has been utilized to determine
the acetylation phenotype (rapid vs. slow acetylator). In
terms of both efficacy and induction of adverse effects, the
most important issue is the generation of DDS-NOH. This
metabolic pathway also occurs in lesional skin of inflam-
matory dermatoses and is thought to be mediated by acti-
vated PMN [156]. Dapsone is distributed to virtually all
organs. Dapsone is retained in skin, muscle, kidneys, and
liver. Trace concentrations of the drug may be presented in
these tissues up to 3 weeks after discontinuation of dapsone
treatment. The drug is also distributed into sweat, saliva,
sputum, tears, and bile. Dapsone is 50–90 % bound to
plasma proteins, whereas MADDS is almost completely
bound to plasma proteins. It crosses the blood–brain barrier
and placenta and is detectable in breast milk [20, 137].
Cases have been reported where dapsone therapy of the
mother resulted in neonatal haemolysis and cyanosis [105].
Approximately 20 % of dapsone is excreted as unchanged
drug via urine, whereas 70–85 % is eliminated as water-
soluble metabolites after conjugation with glucuronic acid.
This step is mediated by uridine diphosphate (UDP)-glu-
curonosyltransferase. Additionally, a small amount might
be excreted in faeces including some yet unidentified
metabolites. The complex metabolic pathway of dapsone
has been reviewed in detail several times [156, 159, 164,
165, 178, 181].
Metabolism of dapsone in cell cultures has not been
studied as extensively [17]. In part, this can be attributed to
the chemical properties of dapsone, which make it a diffi-
cult-to-handle compound [165]. First findings concerning
the metabolism of dapsone in cell cultures were presented
by Drayer et al. [49] and the Canadian group of Uetrecht
et al. [156]. Following incubation of PMN- and zymosan-
activated human PMN with dapsone, high-pressure liquid
chromatography and gas chromatography/mass spectros-
copy demonstrated the production of dapsone hydroxyl-
amine (–NO2), (Fig. 9) and a chlorine-substituted derivative
of dapsone (–Cl) (chlorodapsone) (Fig. 10). Without prior
stimulation, neither DDS-NOH nor the nitro derivative
were detectable. The authors postulate the biotransforma-
tion as depicted in Fig. 3. Activation of leukocytes results in
the induction of the respiratory burst pathway with con-
secutive production of reactive oxygen-species (ROS) such
as 1O2 (singlet-O2), H2O2 or OH
-. During this process,
myeloperoxidase (MPO) uses dapsone as substrate resulting
in the generation of DDS-NOH via oxidation. Finally, by a
further non-enzymatic oxidation process, the nitro deriva-
tive of dapsone is generated (Fig. 11).
Fig. 1 Structural formula of dapsone (4,40diaminodiphenylsulfone)
Fig. 2 The two major
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Controls in cell-free settings using purified myeloper-
oxidase and H2O2 confirmed these findings. In contrast,
adding catalase or sodium azide, respectively, led to a
dose-dependent inhibition of the oxidation of dapsone. The
authors were not able to demonstrate a presumptive alter-
native enzymatic pathway of hydroxylation of dapsone
through the prostaglandin pathway, as classic inhibitors
like acetylsalicylic acid or indometacin did not induce a
decrease of oxidation. Dapsone metabolism in human
mononuclear cells has been demonstrated to be quite
similar [156].
When dapsone is administered, there is equilibrium
between acetylation and deacetylation. Thus, there is the
possibility that PMN in peripheral blood are exposed both
to dapsone and its metabolites. These metabolites like
DDS-NOH have been shown to be pharmacologically
active. However, they have been made responsible not only
for anti-inflammatory mechanisms (e.g., inhibition of
chemotaxis) but also for a number of side effects. To date,
this has been clearly documented for DDS-NOH [35].
Interestingly, Khan et al. [95] recently demonstrated that
human keratinocytes which had been stimulated by various
cytokines like tumor necrosis factor a (TNF-a), interleukin
1b (Il-1b), and interferon c (INF-c) can produce DDS-
NOH as well.
Antimicrobial activity
As an antimicrobial agent, dapsone is bacteriostatic in
action. It inhibits the synthesis of dihydrofolic acid through
by competing with para-aminobenzoic acid for the active
site of dihydropteroate synthetase [35, 41], thus resembling
the action of sulphonamides. Sulfones were found to sup-
press the growth of various pathogenic bacteria such as
streptococci, staphylococci, pneumococci, mycobacteria,
and other strains. The mechanism of action of topical
dapsone in the treatment of acne vulgaris may result from a
combination of both antiinflammatory and antimicrobial
effects. In vitro, dapsone has some antibacterial activity
against Propionibacterium acnes. Owing to its antimicro-
bial activities, dapsone is clearly playing a role in the
treatment of certain infectious diseases (see section
‘‘Indications’’) [67].
Anti-inflammatory mechanisms of action
Animal studies
In the 1970s, dapsone was studied in numerous inflam-
mation models in animals. Experiments were conducted
Fig. 3 Dapsone metabolism in
human PMN and mononuclear
cells after activation by phorbol
myristate acetate (PMA) and
oxidation path by NaOCl
(according to Uetrecht et al.
[156])
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especially with small mammals like mice, rats and guinea
pigs (Table 1). Results of these studies showed wide
variations in anti-inflammatory efficacy. Whereas some
authors were able to demonstrate pronounced anti-inflam-
matory activities (e.g. in anthralin-induced mouse ear
swelling test (MEST), others failed to do so (e.g. in ara-
chidonic acid-induced MEST). Gemmel et al. [64] and
Lewis et al. [102], for example, showed that the antiin-
flammatory action of dapsone differs from that of aspirin-
like non-steroidal anti-inflammatory drugs (NSAID’s).
Hence, it is difficult to draw reliable conclusions
regarding the mechanisms of action of dapsone in sulfone-
sensitive diseases. In this respect, several factors have to be
considered. Amongst others, the inflammation models used
are only poorly characterised on phenotypic and genotypic
levels. Often, dapsone-concentrations applied were con-
siderably exceeding those achieved under therapy. Apart
from that, single dose application cannot be readily com-
pared with repeated doses. Finally, testing conditions var-
ied substantially (e.g. pre-therapeutic vs. post-therapeutic
application of the sulfone). Despite these limitations, dap-
sone can be attributed an anti-inflammatory potential
that—cum grano salis—equals that of classic NSAID’s. In
the following, the impact of dapsone on isolated proin-
flammatory signal transduction pathways and on more
complex disease processes is described in detail.
Reactive oxygen species
Historically, Japanese authors were the first in 1983 to
attribute an oxygen-radical scavenging ability to dapsone
[112–115, 121, 161]. In the works of this group, dapsone
was shown to effectively lower the concentrations of H2O2
and of OH- as well as the activity of chemiluminescence
when these parameters were studied during the process of
oxidative activation PMN. However, dapsone did not alter
the concentration of O2
-. Experiments by van Baar et al.
[unpublished data] confirmed these findings. Furthermore,
the Japanese authors were able to demonstrate an effect of
dapsone to reduce the concentrations of extracellular ROS
as well as that of singulett 1O2. In these experiments the
xanthine/xanthine oxidase system had been tested in the
absence of both PMN and superoxide dismutase (SOD).
Accordingly, the ROS—but not O2
--lowering effect of
dapsone, is unlikely to be mediated by an interaction of
dapsone and SOD. In contrast to these conclusions it was
claimed by later publications that dapsone actually sup-
pressed N-formyl-methionyl-leucyl-phenylalanine
(FLMP)-induced production of extracellular O2
- [43].
More recent studies by Suda et al. [148] yielded compa-
rable data with those of Debol et al. [43]. Suda et al. uti-
lized human PMN, stimulated by FLMP, C5a and PMA
and evaluated any influence of dapsone on the generation
Table 1 Investigations of
dapsone in common animal
inflammatory models
Model Dose range Authors References
A single dose studies mg/kg
Carrageenan-oedema (rat) 36–160 Capstick and
Lewis
[23]
Kaolin-induced oedema (rat) 11–100 Lewis et al. [102]
Zymosan-induced oedema (rat) 10–100 Gemmel et al. [64]
Reverse passive Arthus-type reaction (rat) 10–100
UV erythema (guinea pig) ED50–160 Lewis et al. [102]
B multiple dose studies mg/kg/day
Reverse passive Arthus-type reaction (guinea
pig)
2–5 Ruzicka et al. [131]
Aktive Arthus-type reaktion (guinea pig) 5–50 Thompson and
Souhami
[150]
Cotton wool pellet granuloma (rat) 200 Capstick and
Lewis
[23]
Carrageenan-impregnated 50–200 Lewis et al. [102]
Cotton wool pellet granuloma (rat)
Adjuvant arthritis (rat) 100–200 Capstick and
Lewis
[23]
Lewis et al. [102]
Hypervitaminosis A (rabbit) 25 Barranco [8]
Arachidonic acid-induced mouse ear swelling
test (AA-MEST)
0.1; 1; 5; 10 % Christoph [29]
Anthralin-induced MEST Topically and
systemically
Salomon [135]
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of extracellular O2
- (using a cytochrome C reductase
assay), intracellular O2
- (using flow cytometry), the gen-
eration of elastase and on cytosolic free ionized calcium.
They found dapsone to cause dose-dependant, sizeable
reductions of intracellular O2
- (after induction by FLMP
and C5a) and of extracellular O2
- (Fig. 4a–c). Stikingly, in
these experiments, dapsone appeared to exert little or no
effect on PMA-stimulated O2
- production. The authors
demonstrated an influx of calcium into cells in response to
FLMP. In contrast, PMA failed to mobilize calcium.
Dapsone was seen to inhibit calcium influx in response to
FLMP or C5a. Similarly, dapsone was able to inhibit any
generation of elastase in the presence of FLMP and C5a.
Given that PMA failed to cause an influx of calcium, one
may conclude that dapsone exerts some direct effect on the
intracellular concentrations of free ionized calcium when
the latter was induced by signalling mechanisms [148].
With respect to the O2
- production and the effects of
dapsone in PMN the authors suggested a pathway which is
shown in Fig. 5. The FLMP-induced calcium influx in
PMN and its suppression by dapsone were confirmed by
other laboratories [43].
The role of dapsone in the generation of reactive oxygen
species (ROS) has also been studied in non-phagocytizing
cells [27]. These authors utilized diploid fibroblasts
obtained from human newborns. The cells were stimulated
by paraquat, a herbicide. Paraquat is a known inducer of
oxidative stress. Its effect involves the membrane-bound
NADPH oxidase and the production of superoxide anion.
The intracellular mitochondrial complex may also partici-
pate in this process. In the experiments, dapsone—applied
in different concentrations—leads to a reduction of the
expression of NADPH oxidase 4. Cho et al. [27] found an
inhibition of paraquat-inducible proteinkinase C, of the
mitochondrial complex, and they showed a reduced pro-
duction of cytosolic and mitochondrial superoxide anion.
Moreover, they showed that dapsone as parent compound
does not possess a scavenger function for ROS. In sum-
mary, results of these studies repeatedly disclosed that
Fig. 4 The effect of dapsone on the extracellular superoxide (O2
-)
release induced by N-formyl-L-methionyl-L-leucyl-L-phenyalanine
(fMLP), C5a and phorbol myristate acetate (PMA). Neutrophils
(1 9 106 cells mL-1) were preincubated with or without dapsone at
the concentrations indicated for 30 min and then stimulated with
fMLP (1 lmol L-1) (a), C5a (100 nmol L-1) (b) or PMA
(100 nmol L-1) (c). After addition of cytochrome C (20 lmol L-1),
the reduction of absorbance at 550 nm in the absence (DOD550[SOD])
was measured for 5 min using a single-beam spectrophotometer.
SOD-inhibitable cytochrome C reduction corresponded to DOD550–
DOD550[SOD]. The data shown are representative of three to four
separate experiments with similar results. Dapsone suppressed the
extracellular O2
- production induced by fMLP and C5a but not by
PMA. (according to Suda et al. [148])
Fig. 5 The effect of dapsone on neutrophils. Dapsone suppressed
intra- and extracellular production of superoxide (O2
-) and elastase
release triggered by FLMP and physiological agonist C5a, but not by
PMA. Both FMLP and C5a signaled the above pathways by inducing
calcium influx, but PMA functions bypassed calcium influx. Dapsone
was capable of antagonizing the induction of calcium influx (FMLP:
N-formyl-L-methionyl-L-leucyl-L-phenyalanine, PMA phorbol myris-
tate acetate, PKC protein kinase C, NADPH Nicotinamide adenosine
dinucleotide phosphate) (according to Suda et al. [148]
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dapsone possesses substantial antioxidative properties that
can be attributed in large parts to an inhibition of ROS
production. This calls earlier studies into question that had
ascribed dapsone with direct scavenger function [169].
Apart from this, this experimental study shows for the first
time that experimentally stimulated cells without phago-
cytic properties are capable of producing ROS. In another
experiment, the same group examined the mitochondrial
complex V of Caenorhabditis elegans (C. elegans) and
detected a drop in protein levels in dapsone-treated ani-
mals. Again, dapsone inhibited paraquat-induced release of
H2O2. Finally, the authors could reproduce the same effect
in mammalian muscle cells (male BALB/c mice and
C2C12 cells) [26]. These findings confirmed that not only
stimulated inflammatory cells can generate ROS that are
being down regulated by dapsone.
Myeloperoxidase/halide system
MPO mediates the transformation of H2O2
via halogenation
H2O2 þ Cl !
myeloperoxidase
H2O þ ClO
In a further reaction, ClO- and H2O2 can produce the
release of singlet-O2 and thereby amplify the cytotoxic
potential. It has been generally agreed that part of the anti-
inflammatory activity of dapsone results from a (reversible)
inhibition of MPO. This leads to an inhibition of the con-
version of H2O2 to HOCL. Early works on the mechanisms
of action had already postulated a direct inhibition of MPO
by dapsone [144, 161]. Subsequent studies have confirmed
the inhibitory effect of dapsone on MPO [19, 88, 92, 93,
157]. It is assumed that dapsone exerts a direct inhibition of
MPO which leads to the formation of inactive intermedi-
ates of the enzyme. As hypochlorous acid is an integral part
not only of the antibacterial/antiprotozoal armamentarium
of PMN and eosinophils but can also cause tissue damage
in non-infectious disease states [163], the inhibition of
MPO by dapsone might account for the anti-inflammatory
potential of the sulfone.
Adhesion molecules/cellular adhesion
Leukocyte function antigen (LFA-1) (CD 11 a/CD 18),
Mac-1 (CD 11b/CD 18) and p 150, 95 (CD 11 c/CD 18) are
important members of the b2-integrin family of adhesion
molecules. The effects of dapsone on Mac-1-mediated
adherence of neutrophils of healthy persons were examined
by Booth et al. [16]. They observed a dose-dependent
inhibition of adherence, but only when cells were stimu-
lated with either FMLP or PMA. Adherence of unstimu-
lated cells remained unchanged under the influence of
dapsone. Addition of integrin- b2-antibodies proved that
adherence was indeed integrin-mediated. Yet it is not clear
whether these findings are of relevance in patients treated
with dapsone as the concentrations used exceed those
under therapy by a factor of 10–100. Heidenbluth et al.
[unpublished data] confirmed the ability of dapsone to
interfere with the function of integrins. They examined the
expression of leukocyte integrins LFA1, Mac-1 and p 150,
95 in various cell populations under the influence of dap-
sone (20, 100 and 200 lg/mL). Fluorescence–activated cell
sorter (FACS) analysis was performed in human whole
blood, in isolated PMN and in the macrophage cell line
U937. Stimulation with PMA induced an increased
expression of CD11 a, b, c and CD18 both in PMN and in
U937 cells. Dapsone inhibited the expression of b2-inte-
grins CD11a, CD11c and CD18 in PMN only marginally,
but significantly in U937-cells (CD11c). This effect was
not dose dependent. Thuong-Nguyen et al. [151] showed
that dapsone inhibited adherence of neutrophils to IgA and
IgG from sera of patients with IgA-linear dermatosis and
bullous pemphigoid in a dose-dependent manner. Other
investigators established an inhibition of adhesion of TNF-
a- or platelet activating factor (PAF)-activated PMN of
healthy donors by dapsone [116]. This group used a frozen
section adhesion assay of healthy skin under incubation
with IFN-c and observed an inhibition of neutrophil
adhesion to epidermal cells in a concentration range from
0.1 to 80 lg/mL dapsone. They could also verify that
dapsone down regulates the expression of CD11b on acti-
vated neutrophils.
a-1-Protease inhibitor
In vitro, dapsone possesses a protective effect on elastase
inhibitor capacity of a-1-protease inhibitor (AIP), thereby
showing similar properties as the physiologic antioxidant
ceruloplasmine. Once more, this AIP-protective effect has
been linked to the potent suppression of ROS-production
and to the inhibition of the MPO-halide-system [149]. As
the dapsone concentrations used in this study resemble that
attained in vivo, this action might be useful in the therapy
of diseases with AIP dysfunction.
Chemotaxis
The impact of dapsone on chemotaxis has been studied
with partly conflicting results. A pilot study utilized various
chemotaxins and found a selective inhibition by dapsone in
concentrations resembling those under therapy only when
FMLP was used as stimulus, but not when leukocyte-
derived chemotactic factor (LDCT) and C5a were applied
[72]. Moreover, species- and cell dependency could be
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observed; PMN of guinea pigs and monocytes did not show
inhibition of chemotaxis. Booth et al. [16] examined che-
motaxis and random migration by agarose-technique using
FMLP and IL-8 as stimuli. Dapsone was added in con-
centrations of 30, 100 and 300 lg/mL. Again, a dose-
dependent inhibitory effect of dapsone on chemotaxis of
human neutrophils could be observed (FMLP: 30 lg dap-
sone/mL: 24 % inhibition, 300 lg dapsone/mL: 62 %
inhibition, IL-8: 100 lg dapsone/mL: 24 % inhibition,
300 lg dapsone/mL: 61 % inhibition). Once more, random
migration was also inhibited by dapsone. In vivo studies
produced inconsistent results. A short-term study with
rabbits and guinea pigs which were fed dapsone for 3 days
showed no influence of dapsone on chemotaxis of PMN
[131]. A1h E. coli activated autologous serum even showed
that dapsone induces an increase in chemotaxis in healthy
individuals and in leprosy patients [6]. In a human in vivo
study in healthy volunteers, leukotriene B4 (LTB4) was
applied epidermally to induce chemotaxis as described by
Lammers et al. [100]. In this setting, Salomon demon-
strated that 100 mg dapsone/day does not inhibit LTB4-
induced chemotaxis [135]. This is in consistency with
earlier findings that dapsone therapy does not induce
inhibition of LTB4-induced chemotaxis in the skin of
patients with acne [Prendiville et al., unpublished data].
Further studies with differentially activated sera again
came to nothing [54, 55, 110, 131]. In conclusion, dapsone
inhibits chemotaxis, but only when certain stimuli are
applied. Thus, the statement that dapsone inhibits chemo-
taxis per se can no longer be sustained.
Membrane-associated phospholipid metabolism
Cell activation produces a process of enzymatically med-
iated signal transduction which leads to liberation of ara-
chidonic acid which on her part is source of biologically
active mediators of the cyclooxygenase (COX)- and
lipoxygenase (LOX) pathway. The influence of dapsone on
choline phosphotransferase (ChPhTF) and methyltransfer-
ase I and II (MTF) was examined using PMN, lymphocytes
and erythrocytes of healthy donors [122]. The investigators
found a cell-specific inhibitory effect of dapsone. MTF-
activity in lymphocytes and PMN was inhibited slightly by
high dapsone concentrations, but not that of erythrocytes.
Conversely, erythrocytes showed a significant drop of
ChPhTF-activity in contrast to PMN and lymphocytes
where there was no significant influence. Venom-induced
inflammation following the bite of the brown recluse spider
(loxosceles reclusa) has been linked to an activation of
membrane phospholipids. The venom incorporates a vari-
ety of enzymes (e.g. phospholipase D, esterases, and
hyaluronidase) that are believed to provoke cutaneous and
even systemic effects (viscero-cutaneous loxoscelism).
Using a model of cultivated human keratinocytes, venom-
induced activation of membrane phospholipids could be
confirmed [45]. Whether the well-known therapeutic effi-
cacy of dapsone in the therapy of brown recluse spider
bites can be attributed to the aforementioned mechanism
remains speculative [165].
Prostaglandins
Regarding the inhibition of synthesis and liberation of
prostaglandins by dapsone, there is some evidence pre-
sented by Ruzicka et al. [134]. Using thin layer chroma-
tography, the authors examined the production of
prostaglandin D2 (PGD2) of mast cells that had been
gathered from the plasma and peritoneal caves of Sprague–
Dawley rats under the influence of dapsone (10-2–
10-6 mol/L). Their experiments revealed a dose-dependent
inhibition of the production of PGD2 (IC50: 1 mmol with
exogenous arachidonic acid (AA)-application,
0.2–0.4 mmol with exclusively endogenous AA). Com-
plete suppression was observed with 6 9 10-3 mol or
6 9 10-2 mol, respectively. Washing the cells following
incubation with dapsone completely abolished this effect
pointing to a reversible effect. Moreover, dapsone had a
marked inhibitory effect on IgE-mediated antigen-stimu-
lated production of PGD2 (IC50: 0.2–0.4 mmol). Interest-
ingly, the liberation of histamine was not inhibited. As the
conversion of PGH2 to PGD2 was not influenced by dap-
sone, the target of dapsone can be assumed to be located
before the PGH-PGD-isomerase step. The authors postulate
a direct inhibitory effect on COX. A similar dose-depen-
dent inhibitory effect of dapsone on the production of
PGD2 and 6-keto prostaglandin F1a (6KF1a) by peritoneal
macrophages of mice was described by Bonney et al. [15].
Apart from mast cells and macrophages, human PMN were
examined in respect to a possible inhibition of the COX
pathway [6]. In contrast to clofazimine, dapsone in con-
centrations of 5 and 10 lg/mL inhibited both spontaneous
and FMLP-induced synthesis of PGE2. There was no dif-
ference between the PMN of healthy donors and of leprosy
patients. In summary, the inhibitory effect of dapsone on
prostaglandin synthesis/liberation is beyond doubt.
Leukotrienes
Dapsone is capable of inhibiting the generation of 5-LOX-
products in PMN of healthy donors [171]. PMN were pre-
treated with dapsone in different concentrations
(1.6–100 lmol) subsequently by adding Ca ionophore A
23187 and subsequent incubation. Thereupon, the eicosa-
noids were assessed by reversed-phase high-performance
liquid chromatography (RP-HPLC). Dapsone exhibited
dose-dependent inhibitory activity showing 50 %
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inhibition at 15 lmol for LTB4 with 5 9 10
6. The IC50 of
dapsone for 5-hydroxyeicosatetraenoic acid (5-HETE) and
x-OH-LTB4 amounted to similar values (5-HETE: 9 lmol;
x-OH-LTB4: 11 lmol). In additional experiments, cells
were destroyed with ultrasound and the supernatant incu-
bated with dapsone (1.6–100 lmol) under the addition of
AA. Table 2 depicts the IC50 calculated for LTB4 and
5-HETE in intact PMN and in the cell-free system. The
variations indicate that dapsone also inhibits enzymatic
systems beyond 5-LOX. As subsequent studies demon-
strated, this might be attributed to calcium mobilization
[148]. In rat mast cells, dapsone had a similar inhibitory
effect on 5-LOX [134]. Maloff et al. [107] examined the
effect of dapsone on LTB4-receptors. Using human PMN,
they could demonstrate that dapsone in concentrations of
10, 50 and 100 lmol inhibits the specific binding of LTB4
to the receptor. A further increase of dapsone concentra-
tions did not result in an increase of the blockade. The
exact mechanism of the interruption of the ligand-receptor
signal cascade is not known. In respect to an inhibition of
cysteinyl leukotrienes Bonney et al. [15] examined peri-
toneal macrophages of male Swiss-Webster mice. Stimu-
lation with zymosan led to a time- and dose-dependent
synthesis of leukotrienes and prostaglandins. When dap-
sone was added in concentrations of 50, 100 and 200 lg/
mL, this caused a dose-dependent suppression of LTC4
synthesis. The other two peptido-leukotrienes were not
examined. The inhibitory effect of dapsone on LTC4 pro-
duction could account for the observation that dapsone
possesses corticosteroide-sparing effects in asthma patients
For instance, Berlow et al. [10] could verify that adjuvant
therapy with dapsone (2 9 100 mg/day) reduced the
monthly prednisolone dose from 428 to 82 mg (p \ 0.2) in
patients with chronic, cortisone-dependent asthma. Again,
the exact mechanism of this cortisone-sparing effect is not
known.
Interleukin 8
Interleukin 8 (IL-8), a member of the CXC-chemokine
family, purportedly plays an important role, especially in
neutrophil-mediated inflammation, but has also been
shown to affect other cell species as well (e.g. lympho-
cytes, monocytes, hematopoietic progenitor cells). Signal
transduction is mediated via CXCR1 and CXCR2 receptors
and is involved in viral infections and tumor progression
[117]. Following observations that ROS markedly influ-
ence the regulation of IL-8 [44] studies were initiated that
examined the effect of dapsone on IL 8 in different settings
[44, 80]. In an in vitro model of human whole blood,
dapsone in therapeutic concentrations was shown to exert a
suppressive effect on lipopolysaccharide (LPS)- induced
IL-8 levels [13], an observation that was confirmed by
several study groups. Amongst others, dapsone suppresses
bullous-pemphigoid-IgG-induced IL-8-release from kerat-
inocytes at a posttranscriptional level [139] and is capable
of inhibiting IL-8-mRNA expression [1]. Accordingly,
dapsone blocks IL-8-induced chemotaxis [16, 65]. Fur-
thermore, IL-8 has been shown to be of importance in
neurologic diseases. It is expressed by neurons [174] and
glioblastoma cells have been shown to be affluent sources
of IL-8 [96]. As dapsone shows a suppressive effect on
seizure disorders [103] and inhibits the growth of glio-
blastoma, it is discussed that these effects might be medi-
ated by an inhibitory effect on IL-8 via targeting
neutrophils [85]. Lately, the therapeutic application of
dapsone in glioblastoma was the object of several studies
[85]. However, with the advent of modern molecular-tar-
geted strategies like inhibition of epidermal growth factor
receptor, vascular endothelial growth factor, mammalian
target of rapamycin (mTOR) and others, the value of
dapsone in this field remains doubtful.
TNF-a
Abe et al. [1] examined the influence of dapsone on TNF-a
and other proinflammatory cytokines like IL-1b- and IL-8
in the context of its therapeutic use in lupus erythematosus.
This group used PBMC from healthy donors which were
stimulated with LPS. Dapsone induced a dose-dependent
suppression of TNF-a at mRNA level. With the exception
of IL-8, no influence on the levels of other cytokines was
found. The effect on IL-8 resembled to that already
reported above. It has to be pointed out, however, that the
dapsone concentrations used in this study exceed that under
therapy.
Eosinophil peroxidase
In comparison to the effect on neutrophils, those on
eosinophils have been far less studied. It is likely that
overlapping mechanism play a role (e.g. inhibition of
lipoxygenase, ROS production). Bozmen et al. examined
the influence of dapsone on eosinophil peroxidase [19].
The inhibitory effect of the sulfone on MPO was even
Table 2 IC50 of dapsone for LTB4 and 5-HETE in a cell-free system
(5-LOX) and in intact PMN
IC50 (lM)
Cell free (5-LOX)
(5 9 106 PMN)
Intakt PMN
(5 9 106 PMN)
LTB4 35.0 ± 4.3 15.0 ± 5.6
5-HETE 59.0 ± 5.1 9.0 ± 7.1
Data represent the mean ± SEM of at least three separate
experiments
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stronger than that in neutrophils and associated with a
reduced production of toxic hypochlorous acid and other
ROS. Consecutively, the effect of eosinophil peroxidase on
mast cells was reduced (e.g. liberation of histamine) [142].
The inhibitory effect on eosinophil peroxidase could pro-
vide at least in part an explanation of the therapeutic effi-
cacy of dapsone in eosinophil-mediated diseases (e.g.
eosinophilic fasciitis).
Complement system, coagulation and fibrinolytic
system, cutaneous proteases
In vitro, an inhibitory effect of dapsone on the alternative
way of complement activation was detected [Millikan
et al., unpublished data]. On the contrary, Katz et al. could
not find an influence of dapsone on the classic or alterna-
tive activation of complement in patients with dermatitis
herpetiformis and in animal experiments [87]. Anecdotal
reports document a normalization of initially decreased
complement factors in immune complex vasculitis under
therapy with dapsone [132, 167]. Certainly, these effects
could be the result of an improvement of the disease per se
and not necessarily be a result of a specific effect of dap-
sone on complement factors. Dapsone had no influence on
plasminogen activator when epidermal cells were incu-
bated with pemphigus antibodies [73]. Finally, the effect of
dapsone on cutaneous proteases was found to be only
minor [60].
Lymphocyte function
Once more, results with regard to lymphocyte function are
in part contradictory. Beiguelman and Pisam [9] described
an inhibition of PHA-induced lymphocyte-transformation
(LZT) by dapsone. In healthy donors who had taken dap-
sone in therapeutic doses for 7 days, a significant inhibition
of PHA-stimulated LZT could be observed [140]. Other
authors could confirm this observation when using other
mitogens like concanavalin A and lepromin [5, 99]. The
influence of dapsone on delayed type hypersensitivity was
examined in a mouse model by Nagata et al. [119]. A daily
clinical dose (1CD) of dapsone taken to be equivalent to
that used in humans was 1.7 ng/kg of body weight. Up to
threefold equivalent doses of dapsone (3CD) exerted no
reduction of carrageenan-induced paw edema. On the other
hand in mice alimentation with dapsone was followed by
an emptying of the paracortical zone of lymph nodes [99].
Interestingly, dapsone loses its antibacterial potency
against inoculated mycobacterium (M. leprae) in thymec-
tomized naked mice, in contrast to mice with normal
immune system [119]. In comparison with T-lymphocytes,
B-lymphocytes are influenced by dapsone to a far lesser
extent. In 20 patients with lepra lepromatosa who were
treated with dapsone 50 mg/day over 12–24 months, there
was no difference in the number of B-lymphocytes when
compared with 26 untreated leprosy patients and 25 healthy
controls [99]. Dapsone did not influence antibody-produc-
ing cells of BALB/c- and C57 BI/6-mice in a plaque-
forming cell assay [119]. Furthermore, Thompson and
Souhami could not find any changes in antibody production
[150]. In contrast to that, Das et al. 1985 [unpublished data]
demonstrated a dose-dependent inhibition of the synthesis
of rabies—specific IgA- and IgG-antibodies by dapsone.
The production of total IgA and IgG was not influenced.
The authors attribute the inhibitory effect on specific B cell
clones to a reduction of antigen-specific T-helper cell
activity. The action of dapsone on Arthus reaction is con-
troversial. Thompson and Souhami [150] as well as Ruzi-
cka et al. [131] observed a dose-dependent suppressive
effect of dapsone in guinea pigs and rabbits. Sulfoxone, a
soluble sulfone, exerted no effect in guinea pigs with C4
deficiency [87].
Animal studies with liver and spleen immune cells (T-
and B-lymphocytes stimulated with concanavalin A and
LPS) revealed a dose-dependent effect of dapsone. At
lower concentrations (1 lmol), dapsone stimulated B- and
T-cell proliferation under the influence of both mitogens,
but inhibited B-cell proliferation at higher concentrations
(150 lmol). The authors claim an immunostimulating
effect of dapsone in lower concentrations but an immu-
nosuppressive in higher concentrations as general principle
[90].
Lifespan of Caenorhabditis elegans
In the light of observations that—despite their disease-
induced socioeconomic drawbacks—life expectancy of
leprosy patients under dapsone therapy is increased, South
Korean authors investigated the effect of dapsone on the
lifespan in multicellular organism [26]. In their anti-aging-
model, dapsone in concentrations equalling that achieved
under therapy induced a marked elongation of the median
lifespan of Caenorhabditis elegans (Fig. 6). The nematode
worm is a small, relatively simple, and precisely structured
organism. C. elegans is one of the most powerful animal
models currently in use for studying the aging process and
lifespan.
Dapsone delayed the induction of aging and was shown
to suppress mitochondrial ROS as well as mRNA of
NADPH-oxidase. Typical scavenger-enzymes like super-
oxide dismutase (SOD), catalase, glutathione peroxidase-/
reductase were not influenced by dapsone. As already
noted, this contrasts with earlier studies which had postu-
lated a scavenger function of dapsone. More precisely,
dapsone seems to inhibit the production of ROS as it has
been shown by molecular studies by Cho et al. [26, 28].
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Interestingly, these authors have identified muscle pyruvate
kinase as the protein target of dapsone in C. elegans.
Additional studies in long-term dapsone therapy leprosy
patients using a ferric-reducing ability assay demonstrated
increased antioxidative capacity in erythrocytes. These
mechanisms could be reproduced in mammalian cells [26].
Experimental and clinical results thus confirm studies in
human fibroblasts [27].
Neuroprotection
Recent research revealed that dapsone can influence
functions of the central nerve system [86, 120, 129, 130,
160]. More precisely, it could be shown that dapsone
suppresses experimentally induced neurotoxicity [138]. In
a pilot study, neuroprotective effects of dapsone could be
demonstrated in stroke patients. Patients were given a
single 200 mg-dose of dapsone within 12 h following the
incident. A follow-up study of 60 days’ duration showed
a significant reduction of National Institute of Health
Stroke Scale (NIHSS) in comparison with a placebo
group [118]. In order to further clarify the protective
mechanism of dapsone, animal ischemia–reperfusion
studies supplied evidence that dapsone exerts an inhibi-
tory effect on lipid peroxidation, MPO, nitric oxide
activity and apoptosis (annexin V, caspase 3 und 9) [46].
Again, this neuroprotective effect of dapsone was attrib-
uted to its antioxidative capacities. Anticonvulsive effects
of dapsone have been described in earlier studies [4, 70,
78]. In the context of neurologic diseases, Japanese
authors have reported successful therapy of steroid-
dependent neuro-Sweet-disease that responded to 75 mg
dapsone/day [141] (see 4.10). The neuro-Sweet-disease is
characterized by multiple neurologic (e.g. meningitis,
encephalitis) and well-known dermatological features (e.g.
painful dull red erythematous plaques) in association with
HLA-Cw1 or B54.
Tumor growth
Following 16 days of inoculation with a continuous sixfold
equivalent dose of dapsone, BALB/c-mice-myeloma cells
growth showed no difference when compared with animals
that had been fed with placebo [119]. In contrast, recent
studies generated results pointing to an anti-cancer activity
of certain dapsone derivatives [3, 12, 25, 71, 124]. At
present, further research in this field is in progress.
Human pharmacology studies
After topical pretreatment with dapsonemetabolites
MADDS und DDS-NOH (both 1 % dissolved in acetone)
for 2 weeks, 10 ng LTB4 was applied on skin of eight
healthy volunteers. Biopsies were taken after 24 h and
PMN were quantified flourometrically using elastase
according to the method of Lammers et al. [100].
MADDS did not exert any inhibitory activity on PMN
trafficking compared with corresponding controls and
untreated area (untreated: 790 ± 450 PMN per 10 lg
skin; p [ 0.05, acetone: 840 ± 578; MADDS:
1099 ± 556), whereas DDS-NOH caused a statistical
significant inhibition of PMN accumulation even
exceeding the effect of the reference clobetasol-17-pro-
prionate (CP) (DDS-NOH: 128 ± 143 PMN; CP:
86 ± 131) [172]. In contrast, the parent compound dap-
sone did not inhibit LTB4-induced chemotaxis of PMN
(see section ‘‘Chemotaxis’’). These in vivo results clearly
demonstrate that dapsone metabolites, especially DDS-
NOH, are pharmacodynamically active (Blasum et al.,
unpublished data). This raises the question whether
attempts to increase the tolerability of dapsone therapy by
trying to decrease the production of DDS-NOH might
inevitably be accompanied by a loss of therapeutic effi-
cacy (see below). In a first-proof-of-concept study with
healthy volunteers there was some evidence that topical
applied dapsone (1 % solved in acetone) per se may have
the potential to reduce UV-induced erythema Salomon
[135] (Fig. 7). In line with this pilot study are results of
experiments with both, dapsone and dapsone metabolites,
MADDS and DDS-NOH. [135]. Skin areas were irradi-
ated with UVB (295 nm, two minimal erythema doses).
Twenty-four hours later, UVB-induced erythema was
quantified and cutaneous blood flow measured using
Laser Doppler Imager. In control skin, tissue blood flow
was measured to be 227 units and was significantly
(p \ 0.05) decreased by dapsone (186 U), DDH-NOH
(154 U), and MADDS (195 U). UVB-induced erythema
was also significantly reduced in DDS-NOH- or MADDS-
treated skin when compared with controls. Thus, these
experiments show that dapsone metabolites exert phar-
macodynamic effects when applied topically to the skin
Fig. 6 Survival curves of Ceanorhabditis elegans (n = 129) treated
with dapsone (2 mmol) during their entire life time compared with
worms that were untreated. (according to Cho et al. [26])
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and may at least equal dapsone in their anti-inflammatory
properties. UVB erythema-suppressing activity of dapsone
was subsequently confirmed by Salomon, who observed
significant inhibitory effects of both topically applied
(0.1–10 %) and systemically applied dapsone (100 mg/day)
on UV-induced erythema in healthy volunteers having sun-
reactive skin type II and III. A theoretical explanation for
the observed erythema-suppressing effect of dapsone could
be the drug’s inhibitory action on prostaglandins. In this
context, it is noteworthy that dapsone—topically and sys-
temically applied—unexpectedly exerted no substantial
effect on anthralin- and sodium dodecylsulfate-induced
erythema in healthy volunteers [135]. Dapsone metabolites
were not used in these investigations.
In another human pharmacology study, dapsone was
found not to possess antipsoriatic efficacy in the psoriasis
plaque test [168].
Unique characteristics of dapsone
The association of antimicrobial/antiprotozoal and anti-
phlogistic effects in a broad range of indications places
dapsone in a unique position in the spectrum of non-ste-
roidal antiphlogistic drugs. Currently, no other drug used in
medicine possesses such a wide variety of beneficial
properties as follows:
1. Combination of antimicrobial/antiprotozoal effects (uti-
lized, e.g. in the treatment of opportunistic infections in
patients with acquired immunodeficiency syndrome).
2. Safety of long-term treatment (e.g., life-long use in
leprosy, long-term or chronic intermittent therapy of
inflammatory dermatoses).
3. Unique powerful disease-specific antiphlogistic activ-
ities (e.g., prompt decrease of pruritus and control of
skin lesions in dermatitis herpetiformis; fast ameliora-
tion of loxoscelism associated with brown recluse
spider bites).
4. Steroid-sparing effects (e.g., long-term treatment in
autoimmune blistering diseases and as an adjuvant
treatment in bronchial asthma).
5. CNS-protective effects (anticonvulsive effects, reduc-
tion of stroke-associated tissue damage, inhibition of
glioblastoma).
Finally, the pharmacoeconomic benefit due to the low
cost of dapsone deserves to be mentioned.
Adverse effects of dapsone
Haematology
As already mentioned, hydroxylamines of dapsone, above
all DDS-NOH, are held responsible for some of its major
adverse effects including met-Hb formation, haemolysis
and agranulocytosis. As DDS-NOH is inevitably formed
during dapsone therapy, all these adverse effects are
obligatory and vary only in intensity. These hematologic
side effects of dapsone have long been recognized and have
been reviewed by various authors [11, 101, 125, 136, 165,
173, 178]. Therefore, they will not be dealt with in detail in
this survey. However, it has to be stressed that glucose-6-
phosphate dehydrogenase (G6PD)-deficient patients are
less susceptible to met-Hb production, but more susceptible
to haemolysis. For instance, patients with G6PD-deficient
erythrocytes reveal about a twofold increase in sensitivity
towards sulfone-induced anaemia. Cyanosis which is usu-
ally associated with mild methaemoglobinemia may occur
during dapsone treatment. Acute methaemoglobinemia
occurs rarely, but may result in dyspnea, anemia, vascular
collapse, and in serious courses finally in death. In patients
who do not have G6PD deficiency acute methaemoglo-
binemia should be treated with intravenous methylene blue
(1–2 mg/kg given by slow injection). The effect is gener-
ally complete within 30 min, but the procedure may need
to be readministered if met-Hb reaccumulates.
Skin
In respect of dermatological side effects, various skin
eruptions have been described [81]. They include exfolia-
tive dermatitis, erythema multiforme, urticaria, erythema
nodosum, morbilliform and scarlatiniform exanthema and
toxic epidermal necrolysis. Dapsone-induced photosensi-
tivity is quite rare, not dose-dependent and might be caused
Fig. 7 Suppression of ultraviolet (UV)-induced erythema with top-
ical applied dapsone (1 % solved in acetone, 48 h after UV
exposition) (right forearm), control: left forearm (UV source: UVB
erythemal effective Hg-lamp VITALUX/OSRAM GmbH, Germany)
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not only by the parent compound dapsone but also by its
metabolites (Fig. 8a, b and point 8.4.) [145].
Rash reportedly occurs in about 30–40 % of AIDS
patients receiving dapsone concomitantly with trimetho-
prim, but less frequently in those receiving dapsone alone.
Despite that observation, a substantial proportion of
patients who do not tolerate co-trimoxazole are able to
tolerate dapsone [41].
Nervous system
Rarely, peripheral neuropathy with primarily motor func-
tion loss has been reported in patients receiving dapsone.
Recovery might occur; however, this may take many
months to several years. Tragic cases of patients who had
ingested dapsone with suicidal intention confirm the ability
of the drug to damage the peripheral nervous system,
including the optic nerve resulting in blindness [77, 91]. In
any case, if any signs of neuropathy show, therapy with
dapsone should be immediately stopped (Figs. 9, 10, 11).
Gastrointestinal effects/hepatic reactions
Adverse Gastrointestinal (GI) effects including anorexia,
abdominal pain, nausea and vomiting can be encountered
in patients receiving dapsone. Due to their potential
severity, hepatic adverse effects deserve special attention.
There are three types of reactions:
1. Isolated abnormalities of liver function tests (e.g.,
increased bilirubin and/or liver enzymes) without
evidence of hepatitis or hepatosis. If any abnormality
is detected, the dosage of dapsone should be decreased
or the drug should be discontinued until the source is
established.
2. Prehepatic jaundice induced by haemolytic anaemia.
Hyperbilirubinemia may occur more often in patients
with G6PD-deficiency. All affected patients should be
monitored periodically after reduction of dapsone
dosage/discontinuation of treatment.
3. Toxic or cholestatic hepatitis in conjunction with
hypersensitivity syndrome (HS). Hepatic coma is
indeed the most frequent cause of death in the
hypersensitivity syndrome [104].
Hypersensitivity syndrome
The most recent study on HS was published in 2012. This
review analyzed all published cases from 1951 (the
beginning of the sulfone area) up to 2009 [104]. Of 492
reports, 114 (17 epidemiologic studies and 97 case reports)
met the criteria to be included in this metaanalysis. All in
all, the cases of 336 patients with HS were analyzed.
Prevalence was calculated as 1.4 % (95 % confidence
interval: 1.2–1.7 %). Latency of HS after initiation of
dapsone treatment was B20 days: 24.5 %; 21–28 days:
35.0 %; 29–35 days: 20.9 %; C36 days: 19.6 %. Maxi-
mum latency was 20 weeks. Nearly all patients presented
with a rash (91.1 %) and fever (96.9 %); 73.7 % showed
Fig. 8 Photoallergic reaction
by dapsone in a female patient
with linear IgA dermatosis (a),
Photo-patch test (5 J/cm2 UVA/
Philips TL09) with dapsone and
the two main metabolites of
dapsone (b), (according to
Sto¨ckel et al. [145])
Fig. 9 Chemical structure of dapsone hydroxylamine
Fig. 10 Chemical structure of chlorodapsone
Fig. 11 Chemical structure of a nitroderivative of dapsone
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lymphadenopathy. Hepatic dysfunction could be detected
in the majority of cases, its severity ranging from abnormal
liver tests over hepatosplenomegaly and jaundice to hepatic
coma. About half of the patients demonstrated haemato-
logic changes (leukocytosis 56.6 %, eosinophilia 43.8 %).
Relevant clinical features of HS are summarized in
Table 3. Following withdrawal of dapsone (and in most
cases therapy with steroids), the majority of patients
(82.3 %) recovered, but nearly 10 % had fatal outcome,
hepatic coma being the most frequent cause of death. As
expected, early discontinuation of dapsone was associated
with a better prognosis. On the other hand, mucosal
involvement, hepatitis, older age and concomitant diseases
which occurred predominantly in third-world countries
were all associated with a higher risk of fatal outcome.
Considering the widespread use of dapsone and the paucity
of reports, and in line with this results of the metaanalysis
HS to dapsone is not a rare adverse effect. It occurs in more
than 1 % of all cases [104].
Some other adverse effects of dapsone with hitherto
unknown mechanisms have been recognized. Fortunately,
most of them are really extremely rare (e.g. albuminuria,
insomnia, psychosis, changes of electrolytes,
atrioventricular block) [41, 165, 177]. Some of these may
be partially attributed to anaemia and/or
methaemoglobinaemia.
Clinical use of dapsone
Indications
Due to its antimycobacterial effects, dapsone is a compo-
nent of rifampicin-based multiple drug regimes for the
treatment of multibacillar and paucibacillary leprosy.
Besides rifampicin, the WHO most notably recommends
combinations with clofazimine [41, 67]. The antiprotozoal
effect of dapsone is used in primary prophylaxis and pre-
vention of recurrence in AIDS patients with pneumocystis
jiroveci pneumonia and toxoplasmosis.
As anti-inflammatory agent, dapsone is employed pri-
marily to treat chronic skin diseases characterized by an
accumulation of neutrophils and/or eosinophils (Table 4).
During the past years, dapsone has been introduced addi-
tionally into the therapy of several other dermatoses,
mostly in combination with other drugs, namely topical or
systemic steroids (Table 5). In the literature there is a huge
number of case reports, clinical studies and epidemiologi-
cal analyses representing beneficial effects of dapsone in
such dermatological entities, collectively termed as sul-
fone-sensitives dermatoses. Despite a large body of evi-
dence the subsequent enumeration is indicating only a
small number of relevant references [21, 30, 31, 56, 62, 65,
68, 74, 82–84, 98, 126, 133, 143, 153, 164, 175, 179].
Finally, there are some conditions in which dapsone was
reported anecdotically as being useful, but initial enthusi-
asm has been tempered with subsequent controversial or
contradictory results and/or a total lack of properly con-
trolled trials showing efficacy. At present, the use of dap-
sone in these entities can thus be advocated only in totally
recalcitrant or refractory cases (see review [173]).
In recent years, dapsone has been employed in a variety
of non-dermatological diseases. Haar et al. [69] compared
the efficacy of dapsone with hydroxychloroquine and a
Table 3 Clinical features of hypersensitivity reaction of dapsone
(HS)
n Total (n-334) %
Latency (days)
B20 40 24.5
21 B 28 57 35.0
29 B 35 34 20.9
C36 32 19.6








Mycosal involvement 53 42.1





Immediately after HS onset 85 33.9
Delayed to HS onset 48 19.1
Timepoint unspecified 118 47.0
Systemic steroid therapy 167 82.3
a Presence of all four cardinal symptoms
Table 4 Dapsone as first choice of treatment in chronic inflammatory
dermatoses
Acropustulosis infantilis [21, 165]
Dermatitis herpetiformis Duhring [41, 56, 87, 144, 165, 178, 179]
Erythema elevatum et diutinum [65, 164, 165, 178]
IgA pemphigus [84, 178]
Linear IgA dermatosis [39, 101, 145, 151, 164, 178]
Prurigo pigmentosa [115, 165]
Subcorneal pustular dermatosis Sneddon–Wilkinson [30, 143, 164,
165, 178]
116 Arch Dermatol Res (2014) 306:103–124
123
combination of both in rheumatoid arthritis (RA). Dapsone
was equally potent as the antimalarial. More than 10
studies have since then proved the efficacy of dapsone in
RA [165]. Certainly, in the face of the introduction of bi-
ologics (e.g. TNF-a antagonists, rituximab and januskinase
inhibitors like tofacitinib), the therapeutic armamentarium
has been broadened to an extent that leaves dapsone a dark
horse in this indication. For eosinophilic fasciitis, there are
impressive case reports about the efficacy of dapsone [142].
Dapsone has been used in several clinical studies in patients
with immune thrombocytopenia (ITP) in which the disease
was refractory against standard therapy [40, 51, 52, 176].
Surprisingly, dapsone showed compelling efficacy both in
adults and in children [40]. This has led to a discussion
among haematologists whether dapsone should be classified
as second-line therapy for patients with ITP. In cortisone-
dependent asthma bronchiale patients, co-medication with
dapsone allowed a reduction of steroid dose. The applica-
tion of dapsone in glioblastoma and seizures has already
been dealt with above (see point 4.16. and Table 6).
With these diseases, dapsone has made its way into the
field of non-dermatological disorders. However, many
scientific questions have not yet been answered and its
definitive status remains to be elucidated.
One topical gel formulation of 5 % dapsone is available
on the US market for treating acne vulgaris. Results of two
large-scale studies (dapsone: n = 1506; vehicle:
n = 1504) show a marginal to moderate reduction of non-
inflammatory lesions compared with placebo after a
12-week treatment period (mean change: 32 % dapsone vs
42 % vehicle) [48]. For treatment of acne in adults, ado-
lescents and children 12 years of age or older, a thin layer
of dapsone gel should be applied to the cleansed affected
areas. Combinations with topical benzoyl peroxide may
result in temporary local yellow or orange discoloration of
the skin and facial hair [41].
Dosage of dapsone in chronic inflammatory dermatoses
The dosage of dapsone in nearly all sulfone-sensitive dis-
orders must be individually titrated to determine the mini-
mum daily dose that effectively controls symptoms.
Typically, initial dosages in adults range from 50 to 100 mg/
day. If the treatment goal is not achieved after 4–6 weeks, a
higher dosage may be tried (150–300 mg/day). Adminis-
tration of higher doses depends on tolerability and the results
of laboratory monitoring. When a favourable response is
attained, the dosage should then be reduced to the minimum
that maintains a satisfactory clinical state.
For administration in children, commercially available
tablets of dapsone can be crushed and dissolved, for example,
in strawberry syrup. Studies evaluating bioavailability of
dapsone after administration of this preparation have not
been published. For some indications in childhood, such as
infantile acropustulosis or eosinophilic folliculitis, a daily
dosage of 2 mg per kilogram of body weight is recom-
mended. Therapy with this dosage, or 4 mg/kg weekly,
results in concentrations equivalent to those reached in adults
receiving 100 mg/day. In the treatment of immune throm-
bocytopenia in children, dapsone was used in a similar dose
of about 2 mg/kg body weight [40].
For topical treatment of acne a twice-daily application is
recommended.
Conclusions for treating patients with dapsone
Contraindications, baseline-monitoring and follow-up
controls
Dapsone is contraindicated in patients who are allergic to
the drug. It should not be administered to patients with
Table 5 Dapsone used in dermatologic entities as an adjunctive
treatment modality
Brown recluse spider bite (loxoscelism) [164, 165, 178]
Bullous pemphigoid [68, 84, 126, 139, 153, 164, 165, 178]
Chronic-idiopathic urticaria/delayed pressure urticariaa
Cutaneous lupus erythematosus [41, 132, 133, 164, 165, 173]
Eosinophilic folliculitis (Ofuji’s disease) [173]
Leukocytoclastic vasculitis/urticaria vasculitis [62, 113, 165]
Lichen ruber pemphigoides [31]
Mucous membrane pemphigoid [74, 98]
Pemphigus vulgaris [68, 83, 84, 98, 165, 178]
Pyoderma gangrenosum [30, 164, 165]
Reccurent neutrophilic dermatosis of the dorsal hands [173]
Relapsing polychondritis [164, 165, 173, 178]
Sweet’s syndrome [141, 178]
a There are some case reports reporting a successful treatment of
patients with chronic-idiopathic urticaria and delayed pressure urti-
caria vor [58, 66, 108]. Recently, dapsone was also investigated in
retrospective or randomized non-blinded trials [14, 24, 42, 53, 75].
The results are confirming beneficial effects for dapsone. The German
S3-guideline for treatment of chronic urticaria, therefore, recom-
mends dapsone amongst cyclosporine, histamine2-receptor antago-
nist, omalizumab and systemics steroids as additional drug of
treatment level 4 [180]








Arch Dermatol Res (2014) 306:103–124 117
123
severe anaemia. Dapsone must be used with caution in the
following conditions:
– Glucose-6-phosphate dehydrogenase deficiency
– Met-Hb-reductase deficiency
– Severe hepatopathy
– Cardiac insufficiency/heart failure
– Pulmonary diseases
– Co-medication with met-Hb-inducing drugs or com-
pounds, respectively
Before initiation of dapsone therapy, patients must
undergo a careful clinical evaluation that includes a com-
plete history and physical examination. Routine laboratory
checks as listed in Table 7 are recommended. Follow-up
visits should include a thorough history to determine
adverse effects and incorporate asking for signs of neu-
ropathy. Laboratory tests include a complete blood count
with differential and reticulocytes count at least every
2 weeks for the first 3–6 months, and then every
2–4 months. Liver and renal function tests and urinalysis
should be performed monthly in the first 3–6 months and
then every 2–4 months. Special caution when treating
patients with dapsone must be considered in those who are
receiving or have been exposed to other drugs or agents
that are capable of inducing met-Hb production or haem-
olysis. In patients with pre-existing anaemia the exact
cause of the condition should be clarified by haematologist.
For treating patients with dapsone there is no threshold
value of haemoglobin. The treatment initiation is based on
a range of individual factors (e.g. age, profession, co-
medication, daily activities, pre-existing pulmonary and/or
cardiac diseases). After initiation of dapsone therapy,
evaluation of met-Hb levels should be carefully addressed.
Different time points are of relevance:
1. Met-Hb generation after a single dapsone dose reaches
its maximum after approximately 6 h and, therefore,
undergoes a time-dependent process. In the early
treatment phase met-Hb should be determined 4–6 h
after ingestion of dapsone, because the maximum level
of met-Hb in peripheral blood is indicative of real
cardiopulmonary risk. For this reason, dapsone intake
should be recommended in the evening in patients with
activity during the day.
2. Approximately 14 days after initiation of treatment,
determination of met-Hb will estimate the level under
steady-state conditions and may also allow evaluation
of patients adherence to therapy.
3. Other met-Hb determinations must be considered at
any time if the patient‘s condition has changed (e.g.,
increased dapsone dosage; clinical complaints, co-
medication with other drugs, starting of smoking, use
of pump water in agricultural regions with potential
content of nitrites/anilines).
Met-Hb levels do not need to be checked if clinical
conditions of the patient remain stable.
Strategies to reduce hematologic adverse effects
N-hydroxylation of dapsone via the 3A-family of isoen-
zymes or CYP 2E1 of the hepatic cytochrome P-450 sys-
tem leads to the production of DDS-NOH, which has been
made responsible for haematologic side effects [35–37, 79,
111, 155]. Against this background, considerable efforts
have been made to increase dapsone tolerance. Cytochrome
p-450 inhibitors like ketoconazole and cimetidine reduced
dapsone-associated formation of met-Hb [32–34, 128]. Co-
administration of cimetidine in dosages of 3 9 400 mg/day
reduced met-Hb-levels by 25–30 % in vivo, whereupon
this effect surprisingly decreased after 3 months. Coleman
recommended to routinely co-administer cimetidine at
higher dapsone doses (e.g. 200 mg/day and more) [38]. It
has to be borne in mind, however, that DDS-NOH pos-
sesses anti-inflammatory effects on its own right. Theo-
retically, suppressing its production might reduce the
therapeutic effects of the parent compound dapsone. This
question has not yet been addressed in studies. As another
strategy, various antioxidants like ascorbic acid and vita-
min E have been examined. Neither a dose of 1000 mg
ascorbic acid/day [89, 127, 146] nor 800 mg vitamin E had
a significant effect on dapsone-induced haemolysis [127].
Only simultaneous application of ascorbic acid and vitamin
E exerted an inhibitory effect on met-Hb formation [127].
The reason for these conflicting results might be attribut-
able to the design of the studies which at that time were not
GCP-based (no randomization, blinding or placebo con-
trols). For daily practice, in cases of pronounced haema-
tologic adverse effects, co-administration of cimetidine
during the first weeks of treatment can be recommended if
there are no alternative treatment modalities.
Table 7 Laboratory evaluation
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Potential risk: concomitant use of local anaesthetics
It is well-known that co-medication with other inductors of
methaemoglobinaemia as phenacetine and sulphonamides
is risky in patients under therapy with dapsone. However,
the risk associated with concomitant application of local
anaesthetics like benzocaine or lidocaine is often neglected
[61]. Cases have been reported where application of local
anaesthetics of the amid or ester type as a spray or cream
resulted in severe methaemoglobinaemia up to 35 %
manifesting right away during surgical procedures. Thus,
patients should always carry a dapsone pass and be
instructed to present it to their doctors. In elective surgery,
dapsone should be stopped a few days earlier. As a pre-
caution, met-Hb levels should be determined before
surgery.
Prevention of photosensitivity
Dapsone is able to suppress UV-induced erythema both
when applied orally and topically [166]. However, allergic
photosensitivity to dapsone cannot be excluded; but
apparently, this is an extremely rare event. So far, less than
20 cases have been reported. As photo-patch tests revealed,
the characteristic sulfone group of the parent compound
and dapsone metabolites is responsible for the allergic
reaction [145]. In view of the suppressive effects of dap-
sone on UV-induced erythema, it might be wise to advise
at least skin type I patients to reckon with increased pho-
tosensitivity when dapsone therapy is stopped.
Cross-allergy between dapsone and sulfonamides
Several lines of evidence suggest that there is no obligatory
cross-reactivity between sulfonamides and other sulfona-
mide-nonantibiotic drugs including dapsone [147]. FDA-
approved label for dapsone states that sulfonamide allergy
does ‘‘not include as a contraindication for dapsone use’’.
Currently, absence of cross-reactivity between dapsone and
sulfonamides was confirmed and ascribed to the differen-
tial chemical structure of these two drugs [162]. In con-
clusion, dapsone is not contraindicated in patients with
sulfonamide-allergy.
Pregnancy
Animal reproduction studies with dapsone have not been
conducted. Dapsone has been tested in rats and rabbits with
concentrations 500- to 800-fold higher than therapeutic
levels, when referenced to AUC-value in female patients
under therapy with a 5 % dapsone gel. In these studies,
dapsone was associated with embryocidal effects [41].
There are, however, no documented noxious effects of
dapsone when used in pregnancy [94]. Especially publi-
cations about the use of dapsone in the therapy of leprosy
suggest that dapsone can be used safely in pregnancy.
Multiple case reports about the use of dapsone in a variety
of diseases support the assumption of innocuousness. [39,
50, 76, 97, 105, 106, 109, 154, 158]. In any case, the risk of
not treating the mother must be weighed up against the risk
for the fetus. Dapsone is labelled by US FDA as drug of
pregnancy category C. Patients should be informed about
the lack of secured data.
In terms of drug interactions and management of acute
toxicity of dapsone, the reader is referred to several
reviews on this topic [7, 35, 41, 165].
Conclusion
Dapsone has been studied by far most frequently in vitro—
under strictly defined experimental settings. Overall,
results of these experiments paint a picture of possible
mechanisms of action of dapsone. In addition, many data
from human in vivo studies are available including expe-
rience in dapsone-sensitive diseases. Nevertheless, we are
still far from really understanding dapsone with its differ-
ing, in part contradictory facets in most non-infectious
diseases. As a result, there are many questions in respect of
the mechanisms of action of dapsone that remain to be
addressed:
1. In past years much progress in developing molecular-
based methods has substantially led to new insights
into mechanisms of action of immunosuppressive and/
or immunomodulating remedies including biologics.
Therefore, to get more detailed information about the
mechanisms of action of dapsone, this panel of
investigations should be used with dapsone (e.g.,
pharmacogenetics) in concentrations comparable with
therapeutic conditions.
2. Most of the experimental and clinical studies have
been conducted with the parent compound dapsone.
Hitherto, the relevance of dapsone metabolites has not
been clarified sufficiently. Modern molecular targeted
analyses can certainly help to rectify these deficits.
This aspect has not yet been addressed at all in the
scientific literature.
3. Experimental clues to a preventive effect of dapsone
on neurotoxicity require further clarification, as the
proposed mechanisms leave room for speculations.
4. Observations of a positive effect of dapsone on
lifespan in the Caenorhabditis elegans model raise
new questions concerning the inhibition of ageing
effects of the sulfone in mammalian cells and
organisms.
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5. Finally, dapsone has experienced a renaissance as
reference molecule in organic chemistry as efforts are
made to synthesize biologically active dapsone ana-
logues like sulfoximine [3, 12, 25, 124]. In this context
the definition of the anti-cancer activity of dapsone
derivatives currently is of special interest.
Despite that bundle of unanswered questions, dapsone
remains an indispensable drug for dermatology and a sci-
entifically fascinating remedy. Discovering dapsone cong-
eners which exhibit the positive therapeutic properties of
the original drug but lack unwanted side effects appears
desirable.
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